Introduction
The title of an editorial about 4 years ago was, 'When to start therapy for HIV infection: a swinging pendulum in search of data' [1] and things have not changed too much since then. We are still searching for the data to guide policy makers concerning this question; however, the pendulum may be swinging back to earlier use of antiretroviral treatment (ART) [2 ] . In part, this concern is due to the findings of recent treatment interruption studies. While these studies were not designed to address the 'when to start' question, it appears stopping ART is not a good idea. Here, we review the findings of ART interruption studies and argue that while the results of the interruption studies do not convincingly address the question of when to start, they do, together with the results of cohort studies, motivate a randomized trial of early ART.
CD4
R count-guided treatment interruption studies
þ cell count-guided ART interruption studies were initiated in part in order to determine whether patients could be spared the toxicities associated with treatment [3] . Five randomized studies of CD4 þ count-guided ART interruption strategies have been reported [4-6,7 , 8 ,9 ]. The Strategies for Management of Anti-Retroviral Therapy (SMART) Trial was the largest of these studies and SMART definitively established that the CD4 þ count-guided interruption strategy used was inferior to continuous ART [9 ] . Two of the other randomized studies had sample sizes of 69 [4] and 74 patients [5, 6] , and were, therefore, too small to reliably assess the effects of treatment interruption on clinical outcomes. The Staccato study randomized 284 patients to CD4
þ -guided ART (stop and start ART at CD4 þ count above 350 and below 350 cells/mm 3 ) and 146 patients to continuous ART [7 ] . Staccato was also under-powered to address serious clinical outcomes as those evaluated in SMART. After approximately 2 years of follow-up, diarrhea and neuropathy were more common in the continuous ART arm, and oral and vaginal candidiasis were more common on the CD4 þ guided arm. In the TRIVACAN Study, 216 patients were randomized to a CD4 þ -guided treatment interruption arm with the same CD4 þ count thresholds as in SMART, and 110 were randomized to continuous ART [8 ]. An increased risk of severe morbidity (WHO stage 3 or 4 event) or death, primarily nonfatal bacterial infections, was found in the CD4 þ -guided interruption arm.
Of note, several small nonrandomized studies, most reported prior to SMART, concluded that interruptions based on CD4 þ count may be safe [10] [11] [12] [13] [14] [15] [16] . These studies lacked power (the largest included 167 patients) and a comparison group. Thus, they did not provide reliable information on the risks and benefits of ART interruption as compared with continuous use of ART.
Current treatment guidelines reflect our current state of knowledge and state 'until further data from randomized controlled trials are available, treatment discontinuation in clinical practice should be avoided outside of a clinical trial' [17] .
The findings from SMART are discussed below as they might relate to the 'when to start' question.
The Strategies for Management of Antiretroviral Therapy Trial
In SMART, a strategy that used CD4 þ cell count to guide the episodic use of ART with the current practice of continuous ART was compared. The continuous ART strategy (the control strategy), denoted 'viral suppression', was defined to be consistent with treatment guidelines at the time the trial was initiated [18] -available antiretroviral regimens were to be used in an uninterrupted manner with the goal of maximal and continuous suppression of HIV replication. The experimental, CD4 þ count-guided strategy, denoted 'drug conservation', entailed episodic use of ART for periods defined by CD4 þ count thresholds. Use of ART was stopped or deferred until the CD4 þ cell count dropped to below 250 cells/mm 3 , at which time ART was to be (re-)initiated and continued until the CD4 þ cell count rose to above 350 cells/mm 3 . Upon confirmation that the CD4 þ cell count was above 350 cells/mm 3 , ART was to be stopped and resumed again when the CD4 þ cell count was below 250 cells/mm 3 . During periods of ART use, the goal was to achieve maximal viral suppression.
All patients had a CD4 þ cell count above 350 cells/mm 3 at study entry. For those patients who were not on ART at entry, the SMART intervention plan mimicked a 'when to start' trial, comparing initiating ART (or reinitiating ART as many patients had previously been on ART) at a CD4 þ cell count above 350 cells/mm 3 immediately following randomization (the continuous ART arm) vs. deferring ART until the CD4 þ cell count declined to below 250 cells/mm 3 (patients randomized to episodic ART).
Between January 2002 and January 2006, 5472 HIVinfected patients with a median CD4 þ cell count of 597 cells/mm 3 were randomized -2720 to the drug conservation group and 2752 to the viral suppression group. The episodic ART strategy was stopped because of a safety risk on 11 January 2006, after an average of 16 months of follow-up. The main findings of SMART have been reported. The risk of AIDS or death, the primary endpoint, was more than twice as great for those in the episodic compared with the continuous ART group [hazard ratio (HR) ¼ 2.6; P < 0.001]. This substantially increased risk for the drug conservation group occurred despite the relatively high CD4 þ cell counts in SMART -most (around 68%) of the patient-time in the drug conservation group during follow-up was spent at CD4 þ cell counts above 350 cells/mm 3 [9 ]. The episodic ART strategy was also associated with an increased risk of a composite endpoint consisting of serious cardiovascular disease (CVD), renal disease or liver disease (HR ¼ 1.7; P ¼ 0.009) and an increased risk of all-cause mortality (HR ¼ 1.8; P ¼ 0.007). Most of the deaths (77 of 85) that occurred were not attributable to AIDS-defining conditions. A nonsignificant increased risk of non-AIDS defining malignancies for the episodic compared with the continuous ART strategy was also found (HR ¼ 1.3; P ¼ 0.40) [19 ] . These findings concerning the increased risk of non-AIDS conditions were unexpected, as some antiretroviral drugs have been associated with complications of CVD [20, 21 ] and of other diseases [22, 23] . Tables 1 and 2 examine the findings of SMART through 11 January 2006 in more detail. Table 1 categorizes AIDS and non-AIDS events separately (i.e. non-AIDS deaths are not combined with AIDS events as in the SMART primary endpoint). Serious AIDS (a composite of AIDS events excluding two less serious opportunistic infections, nonfatal esophageal candidiasis and chronic herpes simplex) and serious non-AIDS (major CVD, renal or hepatic disease, non-AIDS cancers, all non-AIDS deaths) are considered. Overall, rates for serious non-AIDS events were about three times greater than for serious AIDS events (184 vs. 60 patients with an event). Even though the HR (drug conservation/viral suppression) is much greater for serious AIDS compared to serious non-AIDS (3.7 vs. 1.6), the absolute risk difference (drug conservation -viral suppression) is similar for serious non-AIDS and serious AIDS (1.2 for serious non-AIDS and 0.9 per 100 person-years for serious AIDS). For the composite of serious AIDS and serious non-AIDS, the HR is 1.9 (95% confidence interval 1.5-2.5) and the risk difference (drug conservation -viral suppression) is 2.1 per 100 person-years. For each component of this composite outcome, risk was greater for drug conservation than viral suppression patients. Table 2 summarizes the serious AIDS and serious non-AIDS outcomes for two subgroups -those on ART at the time of randomization and those not on ART. Approximately 84% of 5472 patients randomized were taking ART at entry, 5% were ART naïve and the remainder were not taking ART at entry, but had at some point in the past. The increased risk of serious AIDS and non-AIDS diseases associated with deferring use of ART to a CD4 þ cell count of 250 cells/mm 3 applies both to those taking ART and those not taking ART at entry. For the composite of serious AIDS or serious non-AIDS, HRs were 1.9 (P < 0.0001) for those on ART at entry and 2.2 (P ¼ 0.02) for those who were not on ART at entry. Risk differences (drug conservation -viral suppression) for this composite outcome were also similar for those on ART (4.4 vs. 2.3 per 100 person-years; difference 2.0) and those not on ART (4.5 vs. 2.1; difference 2.4).
Cohort data to consider along with findings from The Strategies for Management of Antiretroviral Therapy Trial
Current guidelines for initiating ART draw heavily on data from two large collaborations [24, 25, 26 ]. Data from untreated cohorts indicate that the 6-month rate of AIDS decreases with higher CD4 þ cell counts and is much lower for individuals with a CD4 þ cell count of 350 cells/mm 3 or above than for individuals with counts of 200-349 cells/mm 3 [24, 25, 26 ] . Likewise, data from cohorts that follow patients after the initiation of ART indicate that the hazard of AIDS declines following initiation of ART, even at high CD4 þ cell counts, e.g. above 350 cells/mm 3 [25] . Taken together, these data suggest that initiation of ART above 350 cells/mm 3 would lead to a substantial relative reduction in AIDS events. One reason ART is usually not initiated until the CD4 þ cell count is below 350 cells/mm 3 is that the absolute risk difference (as opposed to relative) in the rates of AIDS or death is small [25, 26 ]. This finding is illustrated in Table 3 with data from the ART Collaboration [26 ] . Cumulative incidence (%) of AIDS or all-cause mortality at 5 years after starting ART is compared for three baseline CD4 These data from the ART Collaboration consider non-AIDS mortality, but not non-AIDS morbidity. Serious morbidity and mortality among patients with CD4
þ cell count greater than 350 cells/mm 3 on and off ART is dominated by conditions other than AIDS [27,28, 29 ,30-32] . Furthermore, data from two large cohort studies indicate that rates of non-AIDS mortality are associated with degree of immunosuppression [29 ,33 ] . Cumulative 5-year percents in Table 3 would likely be much higher if non-AIDS morbidity as defined in SMART was considered. For example, in SMART there were 172 patients who experienced an AIDS event or died from any cause. This number increases by about 38% to 238 when considering the number of patients experiencing the combined endpoint of serious AIDS (excludes those who developed esophageal candidiasis or herpes simplex and survived) or serious non-AIDS, which includes all-cause mortality (Table 1) . If all AIDS events are included, the number of patients who experienced an AIDS or serious non-AIDS event or died is 272, a 58% increase in the number of patients with at least one event. This finding illustrates that many patients with serious events are missed if HIV progression is only measured by AIDS or death. If ART reduces the risk of serious non-AIDS events to the extent suggested by SMART, absolute risk differences in the last column of Table 3 would be expected to be much larger, because even if the expected percentage risk reduction for serious non-AIDS events is less than for AIDS as observed in SMART, incidence of non-AIDS diseases is much greater than AIDS at higher CD4 þ counts, resulting in higher absolute risk reductions.
Consider the following hypothetical example. Suppose starting ART at a CD4 þ cell count of 350 cells/mm 3 or above results in a 5-year cumulative percentage of AIDS or death of 7.5% (this percentage ranges from 5.6 to 11.0% for such patients in the ART Collaboration). Assume that, like SMART, 60% of AIDS or death events are due to serious AIDS and that there are three times as many serious non-AIDS as serious AIDS events (see Table 1 ). This scenario would result in a 5-year percentage for the composite of 9%. Similarly, if starting below 350 cells/mm 3 results in a 5-year cumulative percentage of AIDS or death of 10%, the same assumptions lead to a 5-year cumulative percentage for the composite of 12% -an absolute risk difference of 3% in serious events. This absolute risk reduction is much larger than the differences in the last column of Table 3 and also includes more serious events.
Conclusion
For HIV-infected individuals not taking ART with a CD4 þ cell count of 350 cells/mm 3 or above, there is uncertainty about whether ART should be initiated. The findings from SMART suggest that risks of serious AIDS and serious non-AIDS events might be reduced by initiating ART among patients at CD4 þ cell counts above 350 cells/mm 3 . It is, however, unclear whether the findings from SMART can be generalized to ART-naïve patients (less than 5% were ART-naïve in SMART). Epidemiological studies also suggest that early ART would reduce risks of AIDS and of some non-AIDS diseases. As in other illnesses, however, it is hazardous to assume that people's risk of disease can be modified with ART as predicted by the epidemiological data.
The risk of serious non-AIDS events is likely much higher than the risk of AIDS events in patients with CD4
þ cell counts of 350 cells/mm 3 or above. May et al. [26 ] make the important point that the current definition of AIDS is not a complete marker for progression of disease related to HIV infection and this is particularly true for patients with high CD4 þ cell count, on or off ART.
The present situation seems an ideal time to stop the pendulum swing concerning the 'when to start' question Earlier initiation of antiretroviral therapy Neaton and Grund 115 by the conduct of a randomized trial [34] . Important reductions in morbidity and mortality with early ART are potentially possible, and there is substantial uncertainty as to whether the risk reduction suggested by currently available data will be realized. A large trial on the scale of SMART appears feasible, but is expensive in many ways. It is tempting to rely on smaller studies and epidemiological data. As demonstrated in the case of CD4 þ -guided treatment interruption, however, small or uncontrolled studies and narrow data collection can lead to the wrong answer.
